Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

AMGEN

Filed by THE NICKLES GROUP, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 22, 2025
Income
$60,000.00
Expenses
Not reported
Client
AMGEN
Filing UUID
f08a28b9-05fe-4bc6-8cde-68e45200fa15
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.

Literal federal measure citations: H.R. 1968

HCR · Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.

Literal federal measure citations: H.R. 1968

CPT · Copyright/Patent/Trademark

Monitored issues related to intellectual property.

TAX · Taxation/Internal Revenue Code

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act, and corporate taxes.

Literal federal measure citations: H.R. 1990

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.